// App-Quantinova.ai

6028 : Nivolumab (nivo) vs investigators choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.

Researchers

Presenter

  • Nabil F. Saba

Principal Investigators

  • George R. Blumenschein

  • Joel Guigay

  • Lisa F. Licitra

  • Jerome Fayette

  • Kevin J. Harrington

  • Naomi Kiyota

  • Maura L. Gillison

  • Robert L. Ferris

  • Vijayvel Jayaprakash

  • Mark John Lynch

  • Li Li

  • Peter Brossart

Medical Centers

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Centre Antoine Lacassagne, FHU OncoAge, Nice, France

  • Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

  • Centre Leon Berard, Lyon, France

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • Kobe University Hospital Cancer Center, Kobe, Japan

  • University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA

  • Bristol-Myers Sqiubb, Princeton, NJ

  • University Hospital Bonn, Bonn, Germany

Locations

  • Japan

  • Italy

  • Germany

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Erbitux

  • Docetaxel

  • Nivolumab

Outcome

  • Positive

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02105636

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved